Video

Efficacy of Subsequent Therapies in Advanced Ovarian Cancer

Author(s):

Ritu Salani, MDUrsula A. Matulonis, MD

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

Related Videos
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Marc Machaalani, MD
Nicholas P. McAndrew, MD, MSCE
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Kimmie Ng, MD, MPH
Domenica Lorusso, MD, PhD
Related Content
Andrew Hantel, MD, faculty member, Divisions of Leukemia and Population Sciences, Dana-Farber Cancer Institute
October 9th 2024

Study Finds Doctors and Patients Interested in Environmental Impact of Health Care Decisions

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Joyce N. Barlin, MD, Women’s Cancer Care Associates
October 7th 2024

Gotistobart Plus Pembrolizumab Shows Activity in Platinum-Resistant Ovarian Cancer

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Andrew Hantel, MD
October 4th 2024

Criteria for Cancer Clinical Trials and Treatment Regimens Place Patients of African and Middle Eastern Ancestry at a Disadvantage Due to Natural Blood Test Variability, Study Finds

The KIF18A inhibitor VLS-1488 has received fast track designation from the FDA for platinum-resistant high-grade serous ovarian cancer.
October 3rd 2024

FDA Grants Fast Track Status to VLS-1488 for Platinum-Resistant High-Grade Serous Ovarian Cancer